Back to directory

Hospital Universitari de Bellvitge

Hospital Universitari de Bellvitge

AL Amyloidosis ATTRv ATTRwt AA Amyloidosis

Contact Information

Primary Contact

Fernando de Frutos Seminario

MD PhD

Activity level

  • Patients per year250
  • New diagnoses per year50

Multidisciplinary team

  • HematologyOn-site
  • CardiologyOn-site
  • NephrologyOn-site
  • NeurologyOn-site
  • PathologyOn-site
Other specialists
GastroenterologyHepatologyPulmonologyPrimary CareRheumatologyOrthopaedicsGeneticistsGenetic counsellorsNuclear medicine specialistsCardiac imaging specialistsRadiologistsTransplant programme - heartTransplant programme - kidneyTransplant programme - liverPalliative carePsychology / counsellingSocial work

Diagnostic capabilities

  • EchocardiographyOn-site
  • Cardiac MRI (CMR)On-site
  • Radionuclide imagingOn-site
  • Histopathology (Congo red)On-site
  • Amyloid typingOn-site
  • Genetic testingOn-site
  • Fat aspiration / labial gland biopsyOn-site
  • Organ biopsiesOn-site

Subtype expertise

  • ALYes
  • ATTRvYes
  • ATTRwtYes
  • AAYes

Treatment options

  • Chemotherapy (AL)Available on-site
  • TTR stabilizersAvailable on-site
  • RNA interferenceAvailable on-site
  • Antisense oligonucleotidesAvailable on-site
  • Stem cell transplantAvailable on-site
  • Heart transplantAvailable on-site
  • Kidney transplantAvailable on-site
  • Liver transplantAvailable on-site
Other therapeutic services

Active participation in randomized clinical trials in the ATTR field. Currently participating in the following trial: MAGNITUDE, Deple-TTR, ACT-EARLY, HELIOS-B. TRITON-CM.

Patient support services

Services offered
Psychosocial supportSocial workGenetic counsellingNutritional guidance (dietitian)Specialty pharmacyPatient support groupsPalliative care

Networks & telemedicine

  • Telemedicine / virtual consultationYes
  • Part of a formal amyloidosis networkNo
  • Diagnostic services for other organisationsNo

Last confirmed: 8 April 2026

Listings are self-reported by each center and have not been independently verified by the International Society of Amyloidosis (ISA). Inclusion in this directory does not constitute certification, accreditation, or endorsement by ISA.